MacroGenics and Zai Lab’s Exclusive Collaboration and License Agreement to Develop and Commercialize Margetuximab, MGD013 and TRIDENT™ Molecule in Greater China

Goodwin Procter advised MacroGenics on its exclusive collaboration and license agreement with Zai Lab to develop and commercialize Margetuximab, MGD013 and TRIDENT™ molecule in greater China....

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here